Crewe Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $314K | Buy |
13,048
+762
| +6% | +$19.9K | 0.02% | 181 |
|
|
2026
Q1 | $345K | Buy |
12,286
+33
| +0.3% | +$879 | 0.03% | 162 |
|
|
2025
Q4 | $305K | Buy |
12,253
+335
| +3% | +$8.45K | 0.03% | 172 |
|
|
2025
Q3 | $304K | Sell |
11,918
-1,401
| -11% | -$34.6K | 0.03% | 163 |
|
|
2025
Q2 | $323K | Buy |
13,319
+216
| +2% | +$5.04K | 0.05% | 114 |
|
|
2025
Q1 | $332K | Sell |
13,103
-114
| -0.9% | -$2.98K | 0.05% | 106 |
|
|
2024
Q4 | $351K | Sell |
13,217
-1,253
| -9% | -$34K | 0.05% | 106 |
|
|
2024
Q3 | $419K | Sell |
14,470
-186
| -1% | -$5.43K | 0.05% | 93 |
|
|
2024
Q2 | $410K | Sell |
14,656
-94
| -0.6% | -$2.59K | 0.05% | 119 |
|
|
2024
Q1 | $409K | Buy |
+14,750
| New | +$409K | 0.05% | 114 |
|
|
2023
Q3 | – | Sell |
-13,205
| Closed | -$484K | – | 836 |
|
|
2023
Q2 | $484K | Sell |
13,205
-1,172
| -8% | -$45.6K | 0.07% | 78 |
|
|
2023
Q1 | $587K | Buy |
14,377
+229
| +2% | +$9.89K | 0.09% | 75 |
|
|
2022
Q4 | $725K | Sell |
14,148
-1,367
| -9% | -$65.5K | 0.12% | 62 |
|
|
2022
Q3 | $679K | Buy |
15,515
+770
| +5% | +$37.4K | 0.12% | 57 |
|
|
2022
Q2 | $773K | Buy |
14,745
+2,053
| +16% | +$105K | 0.17% | 41 |
|
|
2022
Q1 | $657K | Buy |
12,692
+3,688
| +41% | +$191K | 0.13% | 45 |
|
|
2021
Q4 | $532K | Buy |
9,004
+550
| +7% | +$27.3K | 0.11% | 45 |
|
|
2021
Q3 | $364K | Sell |
8,454
-55
| -0.6% | -$2.44K | 0.09% | 44 |
|
|
2021
Q2 | $333K | Sell |
8,509
-1,999
| -19% | -$77.7K | 0.08% | 45 |
|
|
2021
Q1 | $381K | Buy |
10,508
+158
| +2% | +$5.61K | 0.09% | 39 |
|
|
2020
Q4 | $381K | Buy |
10,350
+2,072
| +25% | +$76K | 0.15% | 37 |
|
|
2020
Q3 | $288K | Buy |
8,278
+1,712
| +26% | +$60K | 0.14% | 36 |
|
|
2020
Q2 | $204K | Hold |
6,566
| – | – | 0.1% | 49 |
|
|
2020
Q1 | $203K | Sell |
6,566
-73
| -1% | -$2.49K | 0.12% | 43 |
|
|
2019
Q4 | $247K | Buy |
6,639
+73
| +1% | +$2.6K | 0.11% | 49 |
|
|
2019
Q3 | $224K | Sell |
6,566
-40
| -0.6% | -$1.46K | 0.1% | 51 |
|
|
2019
Q2 | $272K | Hold |
6,606
| – | – | 0.09% | 69 |
|
|
2019
Q1 | $266K | Buy |
6,606
+40
| +0.6% | +$1.6K | 0.08% | 48 |
|
|
2018
Q4 | $272K | Hold |
6,566
| – | – | 0.09% | 49 |
|
|
2018
Q3 | $275K | Buy |
+6,566
| New | +$253K | 0.23% | 49 |
|
Other funds holding PFE
Crewe Advisors's PFE Position: Q2 2026 in Review
Crewe Advisors increased its Pfizer (PFE) stake by 6.2% in Q2 2026, buying an estimated $19.9K and bringing the position to 13,048 shares worth $314K. The position accounts for 0.02% of the portfolio, ranked #181.
Crewe Advisors first reported a position in PFE in Q3 2018 and has held it in 30 quarters since. The position peaked at $773K in Q2 2022. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Crewe Advisors held 13,048 shares of Pfizer worth $314K as of Q2 2026.
- Crewe Advisors bought 762 Pfizer shares in Q2 2026, an estimated $19.9K.
- Pfizer made up 0.02% of Crewe Advisors's portfolio in Q2 2026, its #181 holding.
- Crewe Advisors first reported a position in Pfizer in Q3 2018 and has held it in 30 quarters since.
- Crewe Advisors's Pfizer position peaked at $773K in Q2 2022.
- 2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.